InterDigital, Inc. IDCC
Set alert
As of Nov 3, 12:29 PM ET
- YTD
- -1.87%
- 1 year
- -21.21%
- Open
- 318.74
- Prev close
- 315.95
- Mkt cap
- 8.05B
- Vol
- 39.07K
- Avg vol
- 196.84K
- EPS
- 8.98
- P/E
- 34.83
- Div yield
- 0.90%
More statistics
- Low
- 310.55
- High
- 318.74
- Forward P/E
- 31.28
- Beta
- 1.49
- Short ratio
- 14.00
- Inst. own
- 109.44%
- Dividend
- 3.00
- Ex-div date
- Oct 13, 2026
- Earnings
- Feb 4, 2027
- 50-d avg
- 331.71
- 200-d avg
- 317.90
- 1y target
- 462.67
Discussion (2)
Sign in to join the discussion
I have been trading for more than 6 years and Alfred Thomson trading strategy is a system that I always tell people to use, the right strategy when they are trading. His strategy is consistent and accurate which makes it one of the best systems out there. Get to him on telegram @Alfredsignals1
VICKY HANUKA IDCC 3 years ago #2$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.